Title
AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma
Date Issued
01 December 2021
Access level
open access
Resource Type
journal article
Author(s)
Belforte N.
Agostinone J.
Alarcon-Martinez L.
Villafranca-Baughman D.
Dotigny F.
Di Polo A.
Université de Montréal
Publisher(s)
BioMed Central Ltd
Springer Nature
Abstract
Background: The maintenance of complex dendritic arbors and synaptic transmission are processes that require a substantial amount of energy. Bioenergetic decline is a prominent feature of chronic neurodegenerative diseases, yet the signaling mechanisms that link energy stress with neuronal dysfunction are poorly understood. Recent work has implicated energy deficits in glaucoma, and retinal ganglion cell (RGC) dendritic pathology and synapse disassembly are key features of ocular hypertension damage. Results: We show that adenosine monophosphate-activated protein kinase (AMPK), a conserved energy biosensor, is strongly activated in RGC from mice with ocular hypertension and patients with primary open angle glaucoma. Our data demonstrate that AMPK triggers RGC dendrite retraction and synapse elimination. We show that the harmful effect of AMPK is exerted through inhibition of the mammalian target of rapamycin complex 1 (mTORC1). Attenuation of AMPK activity restores mTORC1 function and rescues dendrites and synaptic contacts. Strikingly, AMPK depletion promotes recovery of light-evoked retinal responses, improves axonal transport, and extends RGC survival. Conclusions: This study identifies AMPK as a critical nexus between bioenergetic decline and RGC dysfunction during pressure-induced stress, and highlights the importance of targeting energy homeostasis in glaucoma and other neurodegenerative diseases.
Volume
16
Issue
1
Language
English
OCDE Knowledge area
Neurociencias
NeurologÃa clÃnica
Subjects
Scopus EID
2-s2.0-85108913416
PubMed ID
Source
Molecular Neurodegeneration
ISSN of the container
1750-1326
Sponsor(s)
This work was funded by grants to ADP from the National Institutes of Health (NIH, 1R01EY030838–01) and the Canadian Institutes of Health Research (CIHR, 418809). NB was supported by postdoctoral fellowships from the Fonds de recherche du Québec – Santé (FRQS) and the Groupe de Recherche sur le Système Nerveux Central (GRSNC). NB and JA received training awards from the FRQS-funded Vision Health Research Network (VHRN). ADP holds a Tier 1 Canada Research Chair in Glaucoma and Age-Related Neurodegeneration.
Sources of information:
Directorio de Producción CientÃfica
Scopus